The authors wish to make the following correction to this paper [1]:
In the original publication, in “Section 2.1. Study Design and Participants”, there was a mistake in the initial date of patient recruitment, which should be 4 June 2021, instead of 1 June 2021. The corrected date appears below:
“We conducted a single-center, observational prospective cohort study involving MHD patients between 4 June and 31 December 2021 at Maharaj Nakorn Chiang Mai Hospital, which is an affiliated hospital of Chiang Mai University, Thailand.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Narongkiatikhun, P.; Noppakun, K.; Chaiwarith, R.; Winichakoon, P.; Vongsanim, S.; Suteeka, Y.; Pongsuwan, K.; Kusirisin, P.; Wongsarikan, N.; Fanhchaksai, K.; et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. Vaccines 2023, 11, 715. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).